Product Images Aprepitant

This is a bulk package containing Aprepitant Capsules USP, 125 mg each. It is intended for lot and expiration purposes only and not for dispensing to patients. The package is not child-resistant. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) with limited excursions permitted to 15°C t0 30°C (59°F to 86°F). The usual adult dosage information is available in the accompanying Prescribing Information. This bulk package is manufactured for Glenmark Pharmaceuticals Inc., USA, and is a product of India. For more information, customers can call 1 (888) 721-7115.*

This appears to be the description of a medication called Aprepitant Capsules USP. It provides information about the size of the artwork and the lot and exp. It also contains instructions for storage and the usual adult dosage. The medication is manufactured by Glenmark Pharmaceuticals Inc. in Mahwah, NJ, USA and is a product of India.*

This appears to be a mixture of text related to different products, including a 20mmx52mm unvarnished area product for "LoTi.ExP", and Aprepitant Capsules USP by Glenmark, with each capsule containing 40mg of aprepitant USP. The recommended adult dosage is not provided, so it's best to consult the accompanying Prescribing Information to ensure proper use. The capsules should be stored at temperatures between 20°C to 25°C, with excursions allowed up to 15°C to 30°C. The Glenmark Pharmaceuticals Inc. manufactured the capsules in Mahwah, NJ 07430, USA, and is a product of India. If you have any questions, you can contact 1 (888) 721-7115 or visit www_glenmarkpharma-us._com.*

These are Aprepitant Capsules USP with a potency of 80mg made by the company Gglenmark. The package contains 6 capsules for prescription-only use. The package contains a bulk amount meant for storage under controlled room temperature. It is not child-resistant. The recommended adult dosage is not given in this package. The product is manufactured in India for Glenmark Pharmaceuticals in Mahwah, NJ 07430. For further information, one may contact 1(888) 721-7115. *

The text describes a table showing the percentage of patients in two different studies (Study 1 and Study 2) who received either an Aprepitant Regimen or Standard Therapy. The Aprepitant Regimen was given to 260 patients in Study 1 and 261 patients in Study 2. The Standard Therapy was given to 263 patients in Study 1 and 261 patients in Study 2. The table also shows time frames measured in hours. No additional information is available to understand the context or purpose of the studies.*

This appears to be a table describing two different studies (Study 1 and Study 2) and their results based on a chemotherapy cycle. The table shows the different cycles and the number of patients (N) who were treated with the Aprepitant Regimen and Standard Therapy. Aprepitant is likely a medication that was being tested in the study. However, without more information about the study and the context surrounding the table, it's difficult to provide a more comprehensive description.*